News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
Marinomed Biotech AG evaluates a possible 10% capital increase excluding statutory subscription rights to finance ongoing costs in restructuring proceedings. Management Board to discuss with selected investors for potential transaction -
-
-
COMMUNIQUÉ DE PRESSE
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024, including a decline in revenues compared to 2023. The company aims to stabilize through restructuring and new partnerships -